ResMed (NYSE:RMD – Get Free Report) and Vivos Therapeutics (NASDAQ:VVOS – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings and dividends.
Analyst Ratings
This is a breakdown of current ratings for ResMed and Vivos Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ResMed | 0 | 9 | 7 | 0 | 2.44 |
| Vivos Therapeutics | 1 | 1 | 2 | 0 | 2.25 |
ResMed currently has a consensus price target of $241.69, indicating a potential upside of 8.47%. Vivos Therapeutics has a consensus price target of $2.80, indicating a potential upside of 1,687.99%. Given Vivos Therapeutics’ higher probable upside, analysts clearly believe Vivos Therapeutics is more favorable than ResMed.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ResMed | $5.65 billion | 5.69 | $1.52 billion | $10.43 | 21.36 |
| Vivos Therapeutics | $17.44 million | 0.12 | -$21.17 million | ($1.90) | -0.08 |
ResMed has higher revenue and earnings than Vivos Therapeutics. Vivos Therapeutics is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
ResMed has a beta of 0.77, meaning that its stock price is 23% less volatile than the S&P 500. Comparatively, Vivos Therapeutics has a beta of 6.04, meaning that its stock price is 504% more volatile than the S&P 500.
Institutional & Insider Ownership
55.0% of ResMed shares are owned by institutional investors. Comparatively, 26.4% of Vivos Therapeutics shares are owned by institutional investors. 0.7% of ResMed shares are owned by insiders. Comparatively, 2.1% of Vivos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Profitability
This table compares ResMed and Vivos Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ResMed | 26.94% | 25.58% | 18.89% |
| Vivos Therapeutics | -122.00% | -2,325.64% | -102.01% |
Summary
ResMed beats Vivos Therapeutics on 11 of the 14 factors compared between the two stocks.
About ResMed
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients’ device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN’s software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
About Vivos Therapeutics
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.
Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.
